![](https://webarchive.library.unt.edu/eot2008/20090509215559im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509215559im_/http://www.cancer.gov/images/spacer.gif)
renal cell carcinoma peptides vaccine IMA901 A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509215559im_/http://www.cancer.gov/images/spacer.gif)
Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090509215559im_/http://www.cancer.gov/images/spacer.gif) | IMA901 | | ![](https://webarchive.library.unt.edu/eot2008/20090509215559im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509215559im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509215559im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509215559im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509215559im_/http://www.cancer.gov/images/spacer.gif) |